David Lebwohl

12.6k total citations · 8 hit papers
43 papers, 9.6k citations indexed

About

David Lebwohl is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, David Lebwohl has authored 43 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in David Lebwohl's work include Cancer Treatment and Pharmacology (18 papers), Colorectal Cancer Treatments and Studies (9 papers) and PI3K/AKT/mTOR signaling in cancer (7 papers). David Lebwohl is often cited by papers focused on Cancer Treatment and Pharmacology (18 papers), Colorectal Cancer Treatments and Studies (9 papers) and PI3K/AKT/mTOR signaling in cancer (7 papers). David Lebwohl collaborates with scholars based in United States, Germany and Switzerland. David Lebwohl's co-authors include William J. Berg, Eric Van Cutsem, Andrea Kay, James C. Yao, Edward M. Wolin, Marianne Pavel, Kjell Öberg, T Haas, Norbert Hollaender and Robert J. Motzer and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

David Lebwohl

42 papers receiving 9.3k citations

Hit Papers

Efficacy of everolimus in advanced renal cell carcinoma: ... 2008 2026 2014 2020 2008 2011 2011 2013 2012 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    2008 2.3k citations Robert J. Motzer, Bernard Escudier et al. The Lancet profile →
  2. Everolimus for Advanced Pancreatic Neuroendocrine Tumors
    2011 2.1k citations James C. Yao, Manisha H. Shah et al. New England Journal of Medicine profile →
  3. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
    2011 767 citations Marianne Pavel, John D. Hainsworth et al. The Lancet profile →
  4. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
    2013 629 citations John J. Bissler, J.C. Kingswood et al. The Lancet profile →
  5. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
    2012 578 citations David Neal Franz, Е. Д. Белоусова et al. The Lancet profile →
  6. Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
    2009 487 citations James C. Yao, Catherine Lombard‐Bohas et al. Journal of Clinical Oncology profile →
  7. Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
    2013 383 citations Denise A. Yardley, Shinzaburo Noguchi et al. Advances in Therapy profile →
  8. Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
    2013 379 citations Tarek Sahmoud, David Lebwohl et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Lebwohl United States 26 5.3k 3.4k 3.3k 3.0k 2.0k 43 9.6k
Tarek Sahmoud Belgium 41 5.1k 1.0× 2.1k 0.6× 4.9k 1.5× 1.4k 0.5× 424 0.2× 130 11.3k
Emily K. Bergsland United States 45 7.1k 1.3× 3.1k 0.9× 1.8k 0.5× 3.4k 1.1× 2.3k 1.2× 202 10.9k
Helen X. Chen United States 37 4.1k 0.8× 3.9k 1.1× 2.6k 0.8× 715 0.2× 1.6k 0.8× 84 8.9k
Charles M. Baum United States 35 4.7k 0.9× 5.9k 1.7× 8.2k 2.5× 952 0.3× 1.0k 0.5× 71 12.8k
Michele Reni Italy 59 6.1k 1.2× 2.0k 0.6× 3.0k 0.9× 1.9k 0.6× 2.1k 1.0× 321 11.4k
Rosine Guimbaud France 34 7.7k 1.5× 1.5k 0.4× 2.5k 0.8× 2.0k 0.7× 445 0.2× 178 9.5k
Christine Chevreau France 54 6.2k 1.2× 6.3k 1.8× 10.2k 3.1× 670 0.2× 937 0.5× 310 15.6k
Haruyasu Murakami Japan 40 3.8k 0.7× 1.4k 0.4× 3.7k 1.1× 689 0.2× 417 0.2× 306 6.1k
Xin Huang United States 37 5.4k 1.0× 2.8k 0.8× 7.1k 2.1× 758 0.3× 859 0.4× 98 10.2k
Daniel Castellano Spain 47 5.3k 1.0× 2.5k 0.7× 4.0k 1.2× 1.4k 0.5× 786 0.4× 368 9.5k

Countries citing papers authored by David Lebwohl

Since Specialization
Citations

This map shows the geographic impact of David Lebwohl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Lebwohl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Lebwohl more than expected).

Fields of papers citing papers by David Lebwohl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Lebwohl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Lebwohl. The network helps show where David Lebwohl may publish in the future.

Co-authorship network of co-authors of David Lebwohl

This figure shows the co-authorship network connecting the top 25 collaborators of David Lebwohl. A scholar is included among the top collaborators of David Lebwohl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Lebwohl. David Lebwohl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yardley, Denise A., Shinzaburo Noguchi, Kathleen I. Pritchard, et al.. (2013). Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Advances in Therapy. 30(10). 870–884. 383 indexed citations breakdown →
2.
Bissler, John J., J.C. Kingswood, Elżbieta Radzikowska, et al.. (2013). Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. 381(9869). 817–824. 629 indexed citations breakdown →
3.
Franz, David Neal, Е. Д. Белоусова, Steven Sparagana, et al.. (2012). Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. The Lancet. 381(9861). 125–132. 578 indexed citations breakdown →
4.
Wilson, P. M., Dongyun Yang, Mizutomo Azuma, et al.. (2012). Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib). The Pharmacogenomics Journal. 13(5). 410–416. 16 indexed citations
5.
Giatromanolaki, Alexandra, Michael I. Koukourakis, Efthimios Sivridis, et al.. (2012). Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials. British Journal of Cancer. 107(7). 1044–1050. 16 indexed citations
6.
Yao, James C., Manisha H. Shah, Tetsuhide Ito, et al.. (2011). Everolimus for Advanced Pancreatic Neuroendocrine Tumors. New England Journal of Medicine. 364(6). 514–523. 2078 indexed citations breakdown →
7.
Lebwohl, David, George Thomas, Heidi A. Lane, et al.. (2011). Research and innovation in the development of everolimus for oncology. Expert Opinion on Drug Discovery. 6(3). 323–338. 25 indexed citations
8.
Grimminger, Peter, Carl Barrett, David Lebwohl, et al.. (2011). TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials. The Pharmacogenomics Journal. 12(5). 404–411. 33 indexed citations
9.
Yao, James C., Catherine Lombard‐Bohas, Éric Baudin, et al.. (2009). Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial. Journal of Clinical Oncology. 28(1). 69–76. 487 indexed citations breakdown →
10.
Yuan, Ruirong, Andrea Kay, William J. Berg, & David Lebwohl. (2009). Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. Journal of Hematology & Oncology. 2(1). 45–45. 188 indexed citations
11.
Lebwohl, David, et al.. (2009). Progression-Free Survival. The Cancer Journal. 15(5). 386–394. 42 indexed citations
12.
Motzer, Robert J., Bernard Escudier, Stéphane Oudard, et al.. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. The Lancet. 372(9637). 449–456. 2339 indexed citations breakdown →
13.
Awada, Ahmad, Martine Piccart, Suzanne F. Jones, et al.. (2008). Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy. Cancer Chemotherapy and Pharmacology. 63(3). 417–425. 20 indexed citations
14.
15.
Safran, Howard, Carsten Bokemeyer, Manish A. Shah, et al.. (2006). A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Investigational New Drugs. 24(5). 441–446. 28 indexed citations
16.
Sternberg, Cora N., Peter Whelan, John Hetherington, et al.. (2005). Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer. Oncology. 68(1). 2–9. 167 indexed citations
17.
18.
Hainsworth, John D., Howard A. Burris, Dana S. Thompson, et al.. (2002). Phase I Study of JM-216 (an Oral Platinum Analogue) in Combination with Paclitaxel in Patients with Advanced Malignancies. Investigational New Drugs. 20(1). 55–61. 15 indexed citations
19.
Trudeau, Marc, Gavin Stuart, Hal W. Hirte, et al.. (2002). A Phase II Trial of JM-216 in Cervical Cancer: An NCIC CTG Study. Gynecologic Oncology. 84(2). 327–331. 21 indexed citations
20.
Khoo, K., L. J. Brandes, Leonard Reyno, et al.. (1999). Phase II Trial of N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and Doxorubicin Chemotherapy in Metastatic Breast Cancer: A National Cancer Institute of Canada Clinical Trials Group Study. Journal of Clinical Oncology. 17(11). 3431–3437. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tarek Sahmoud Breakdown of academic impact, for papers by Emily K. Bergsland Breakdown of academic impact, for papers by Helen X. Chen Breakdown of academic impact, for papers by Charles M. Baum Breakdown of academic impact, for papers by Michele Reni Breakdown of academic impact, for papers by Rosine Guimbaud Breakdown of academic impact, for papers by Christine Chevreau Breakdown of academic impact, for papers by Haruyasu Murakami Breakdown of academic impact, for papers by Xin Huang Breakdown of academic impact, for papers by Daniel Castellano
Rankless by CCL
2026